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 Abstract
AIM: The aim of this study was to measure the prevalence of myeloproliferative disorders in a sample of Iraqi patients 
and to measure the changes in patients’ blood parameters.
BACKGROUND: Myeloproliferative disorders are a group of neoplasms affecting the bone marrow progenitor cells 
characterized by excess cells with a risk of transforming to acute leukemia. There is a gap in knowledge about 
the prevalence of Iraqi population. Thus, we investigated the prevalence and distribution of different types of 
myeloproliferative disorders in a sample of Iraqi patients.
MATERIALS AND METHODS: Cross-sectional study is done at the National Center of Hematology from November 
2019 till March 2020 on 75 patients who were diagnosed by a specialist hematopathologist to have one subtype 
of myeloproliferative disorders (MPDs). Blood samples were taken from them and analyzed to get complete blood 
count, blood film, bone marrow aspirate, and biopsy that were analyzed for each patient. Blood samples were taken 
from them and analyzed in terms of blood indices, which include red blood cells, white blood cells, and platelets.
RESULTS: The 75 patients were found to be comprising 35 chronic myelogenous leukemia (CML) patients (46.7%), 
myelofibrosis 22 patients (29.3%), essential thrombocythemia (ET) 9 patients (12%), and polycythemia vera (PV) 
9 patients (12%). In terms of male/female ratios, they were as follows: Myeloproliferative neoplasms (MPNs) male-
to-female ratio is 1.2, CML= 0.94, myelofibrosis= 2.14 and ET= 0.5 and PV male-to-female ratio is 2.
CONCLUSIONS : MPN male-to-female ratio in Iraq, which is 1.2, CML is the most common subtype. Regarding 
myelofibrosis, in our study, the male-to-female ratio is 2.14, which is much higher other countries. This could be 
attributed to high exposure to benzene and toluene which are well known to be causative agents for myelofibrosis. 
Regarding ET or PV, the male-to-female ratios were compatible with other countries.
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 Introduction
Myeloproliferative neoplasms (MPNs) are a 
category of bone marrow illnesses that contain excess 
cells, previously known as myeloproliferative disorders. 
They are connected to myelodysplastic syndrome and 
acute leukemia and can develop them, but overall 
myeloproliferative diseases have a far better prognosis.
This type of disease was changed from 
“myeloproliferative diseases” to “myeloproliferative 
neoplasms” in the World Health Organization’s new 
classification of hematologic malignancies [1]. This 
reflects the clonally underlying genetic differences 
which are a central aspect of this disease group.
Classification: In 2016, MPD types were listed 
by the World Health Organization [2]:
1. Chronic myelogenous leukemia (BCR-ABL1–
positive) (CML)
2. Chronic neutrophilic leukemia
3. Polycythemia vera (PV)
4. Primary myelofibrosis
5. Essential thrombocythemia (ET)
6. Chronic eosinophilic leukemia (not otherwise 
specified)
7. Mastocytosis.
Causes
All MPNs originate from the myeloid lineages 
precursors in the bone marrow. MPNs are attributed to 
DNA mutations. These mutations were studied thoroughly: 
1. Philadelphia chromosome-negative cases 
have MPL or JAK2 mutation [1]
2. CALR mutations were found in [3] JAK2 and 
MPL-negative myelofibrosis and ET [4]
3. Others: Mutations in the genes LNK, CBL, 
TET2, ASXL1, IDH, and IKZF1 [5].
Diagnosis
Diagnostic tests may involve an assessment 
of red cell mass (for polycythemia), aspiration to the 
bone marrow, depending on the existence of MPN 
and trephine biopsy, levels of arterial oxygen, and 
carboxyhemoglobin, alkaline neutrophil, Vitamin B12, 
serum urate [6], or DNA sequencing [7].
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Aim
The aims of this study were as follows:
1. To measure the prevalence of myeloproliferative 
disorders in a sample of Iraqi patients
2. To measure the changes in patients’ blood 
parameters.
Materials and Methods
A cross-sectional study was done at 
the National Center of Hematology/Baghdad/Iraq from 
November 2019 till March 2020 on 75 patients who 
were diagnosed by a specialist hematopathologist 
to have one subtype of MPDs. Inclusion criteria: Any 
patient with MPD, regardless of age and gender, was 
included in the study. Exclusion criteria: None.
Blood samples were taken from them and 
analyzed to get a complete blood count using an 
automated electronic counter (hematology auto-
analyzer - BECKMAN COULTER, ACT. 5 diff. 
USA).  Blood samples were taken from them and 
analyzed in terms of blood indices which include red 
blood cells (RBCs), white blood cells (WBCs), and 
platelets.
Blood film, bone marrow aspirate, and biopsy 
were analyzed for each patient.
The study protocol was approved by our 
Institutional Review Board and conformed to the 
principles of the Declaration of Helsinki. After obtaining 
formal written consent from each patient, data were 
prepared as frequencies, relative frequencies.
Data were presented in frequencies and 
percentages and analyzed using Student T-test and 
ANOVA test when applicable using Graph pad 8 
software and p = 0.05 as the significance level.
Results
Seventy-five patients were enrolled in this 
study, males 41 (54.7%) and females 34 (45.3%) with 
their blood indices, as shown in Table 1.
Then, patient samples were analyzed in-depth 
for blood indices according to sex (Table 2).
Blood film samples analysis is shown in Table 3, 
showing the prevalent hematologic phenotypes. The 
most common are CML (13 cases) and leukocytosis 
with the left shift (12 cases).
Table 1: Absolute blood indices of recruited patients in terms 
of mean and standard deviation and range
Parameters Mean ± SD (Range)
WBC count (×103)/µl 62.35 ± 71.91 (2.06–243.96)
Neutrophils (×103)/µl 52.23 ± 62.72 (0.66–218.1)
Lymphocytes (×103)/µl 5.73 ± 5.59 (0.68–25.45)
Monocytes (×103)/µl 1.48 ± 2.16 (0.03–11.72)
Eosinophils (×103)/µl 0.68 ± 0.99 (0–4.47)
Basophils (×103)/µl 2.25 ± 4.46 (0–20.94)
RBC count (×106) /µl 4.54 ± 1.86 (0.1–8.5)
Hb g/l 12.16 ± 3.25 (3.7–22.5)
HCT l/l 34.79 ± 11.28 (9.8–66.4)
MCV Fl 77.73 ± 13.21 (28–125.1)
MCH Pg 29.69 ± 10.32 (14.8–75.7)
MCHC g/l 36.65 ± 9.02 (26.5–79.5)
RDW % 19.26 ± 5.87 (10.9–42)
Platelets count (×103)/µl 402.60 ± 285.21 (15.4–1184)
RBC: Red blood cells, WBC: White blood cells.
Table 2: Absolute blood indices of recruited patients (males 
and females) in terms of mean and standard deviation and 
range (in brackets)
Parameters Male (n=41) Female (n=34) p-value
WBC count (×103)/µl 55.5 ± 69.6 (2.51-212.23) 70.6 ± 74.9 (2.06-243.96) 0.370
Neutrophils (×103)/µl 46.4 ± 59.3 (0.66-187.4) 59.3 ± 66.9 (1.07-218.1) 0.381
Lymphocytes (×103)/µl 5.22 ± 5.49 (0.68-20) 6.34 ± 5.73 (0.77-25.45) 0.391
Monocytes (×103)/µl 1.29 ± 2.03 (0.04-10) 1.69 ± 2.31 (0.03-11.72) 0.427
Eosinophils (×103)/µl 0.51 ± 0.77 (0-3.45) 0.88 ± 1.18 (0.01-4.47) 0.101
Basophils (×103)/µl 2.10 ± 4.44 (0-20.94) 2.43 ± 4.54 (0-18.23) 0.750
RBC count (×106) /µl 4.79 ± 1.94 (0.1-8.2) 4.23 ± 1.73 (1.6-8.5) 0.198
Hb g/l 12.58 ± 3.62 (3.7-22.5) 11.66 ± 2.72 (5.3-19.3) 0.225
HCT l/l 36.57 ± 12.01 (9.8-66.4) 32.64 ± 10.10 (16.3-57.7) 0.134
MCV Fl 75.6 ± 13.1 (28-96.1) 80.4 ± 13.0 (54.8-125.1) 0.117
MCH Pg 29.45 ± 12.03 (14.8-75.7) 29.98 ± 7.98 (18.6-49) 0.827
MCHC g/l 36.13 ± 9.56 (26.5-79.5) 37.28 ± 8.41 (29.5-63.8) 0.587
RDW % 18.45 ± 4.58 (11.8-35.1) 20.23 ± 7.07 (10.9-42) 0.191
Platelets count (×103)/µl 354.0 ± 245.3 (15.4-921) 461.2 ± 320.9 (59-1184) 0.106
*Significant difference between two independent means using Student-t-test at 0.05 level. RBC: Red blood 
cells, WBC: White blood cells.
Table 3: Hematologic phenotypes according to the analysis of 
blood film
Blood film No
CML 13
Dicytopenia 7
Dicytopenia with neutrophilia 1
Dicytosis 4
Hypochromic microcytic anemia with leukocytosis 1
Hypochromic normocytic RBCS 1
Hypochromic RBCs with erythrocytosis 1
Leukocytosis with left shift 12
Mild normochromic anemia with relative neutrophilia 1
Moderate normochromic anemia 1
Moderate normochromic anemia, relative neutrophilia 1
MPN 4
MPN mostly CML 14
MPN mostly ET 1
Normochromic anemia 2
Pancytopenia 3
Pancytosis 5
Thrombocytosis 2
Thrombocytosis and leukocytosis 1
RBC: Red blood cells.
The analysis of bone marrow aspirate, as 
shown in Table 4, reveals that the prevalent hematologic 
phenotype is CML (21 cases) as the most common.
Table 4: Hematologic phenotypes according to the analysis of 
bone marrow aspirate
BM aspirate No
CML 27
Dry tap 21
MPN 14
MPN (CML) 4
MPN mostly ET 5
MPN mostly PV 3
Normo cellular marrow 1
The analysis of bone marrow aspirate, as 
shown in Table 5, reveals the hematologic phenotypes 
with MPN, mostly CML, as the most prevalent (24 
cases).  There  are  two  types  of  ET:  one  with  fibrosis 
and  the  other  is  without. This means that there is a 
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fibroblastic reaction in BM of these patients which could 
be alarming findings of progression or transformation of 
ET to mycosis fungoides (MFs) disease.
Table 5: Hematologic phenotypes according to the analysis of 
bone marrow biopsy
BM biopsy No
CML 30
MPN 3
MPN (CML) 2
MPN (myelofibrosis) 1
MPN mostly ET 6
MPN mostly ET with fibrosis 2
MPN mostly MF 1
MPN mostly PV 9
Myelofibrosis 21
MF: Mycosis fungoides
Then, final diagnosis of patient samples 
with frequency and percentages of total is shown in 
Table 6.
Table 6: The subtype of MPN of patient samples showing the 
types frequency and percentage from total
Final diagnosis No %
CML 35 46.7
Myelofibrosis 22 29.3
ET 9 12.0
PV 9 12.0
By analyzing the samples according to blood 
parameters,  we got the analysis first for WBC count, 
as shown in Table 7. CML has the highest WBC count
Table 7: WBC count in different types of myeloproliferative 
disorders in terms of mean ± SD and range. Data are illustrated 
in a relevant figure
Final diagnosis No WBC count (x103)/µl
Mean ± SD Range
CML 35 115.8 ± 73.0 10.35–243.96
Myelofibrosis 22 17.1 ± 25.2 2.06–117.82
ET 9 14.1 ± 6.1 3.84–20.94
PV 9 13.3 ± 6.1 5.31–25.06
p-value 0.0001*
WBC: White blood cells.
Then, looking at the neutrophil count,  we got 
Table 8 which shows CML with the highest neutrophil 
count as compared with other myeloproliferative 
disorders.
Table 8: Neutrophil absolute count in different types of 
myeloproliferative disorders in terms of mean±SD and range. 
Data are illustrated in a relevant figure
Neutrophil count (×103)/µl
Final diagnosis No Mean ± SD Range
CML 35 98.5 ± 64.7 8.02–218.10
Myelofibrosis 22 13.1 ± 18.9 0.66–86.01
ET 9 9.9 ± 5.2 2.34–16.75
PV 9 10.1 ± 6.1 2.60–23.65
P value 0.0001*
The eosinophil count was highly variable, but it 
is the highest with CML (Table 9).
Table 9: Eosinophil count in different types of myeloproliferative 
disorders in terms of mean±SD and range. Data are illustrated 
in a relevant figure
Eosinophil count (×103)/µl
Final diagnosis No Mean ± SD Range
CML 35 1.1 ± 1.2 0.04–4.47
Myelofibrosis 22 0.1 ± 0.1 0–0.40
ET 9 0.7 ± 0.9 0.06–3.00
PV 9 0.3 ± 0.2 0.02–0.45
p-value
Similarly, the basophil count is the highest with 
CML (Table 10).
Table 10: Basophil count in different types of myeloproliferative 
disorders in terms of mean±SD and range. Data are illustrated 
in a relevant figure
Basophil count (×103)/µl
Final diagnosis No Mean ± SD Range
CML 35 4.6 ± 5.7 0.07–20.94
Myelofibrosis 22 0.2 ± 0.6 0–2.59
ET 9 0.2 ± 0.4 0–1.20
PV 9 0.2 ± 0.3 0–0.74
p-value
In terms of hemoglobin level, the highest level is 
with polycythemia, and the lowest is with meylofibrosis 
(Table 11).
Table 11: Hemoglobin level in different types of myeloproliferative 
disorders in terms of mean±SD and range. Data are illustrated in 
a relevant figure
Hb g/l
Final diagnosis No Mean ± SD Range
CML 35 12.5 ± 2.1 9.5–17.4
Myelofibrosis 22 10.5 ± 3.7 3.7–22.5
ET 9 11.0 ± 2.7 5.3–14.1
PV 9 16.0 ± 3.2 8.9–19.3
p-value 0.0001*
Finally, platelets count is the highest with ET 
and the lowest with meylofibrosis (Table 12).
 Discussion
Up to our knowledge, this is the first 
epidemiological study about MPNs in Iraq. The diversity 
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of the various types of MPN has made full characterization 
of their symptom profiles challenging. PV, ET, and MF 
may concurrently shorten survival and impair quality 
of life. For decades, gender differences in MPN have 
been observed and documented but remained of low 
investigational priority given the paucity of exploratory 
tools.
Table 12: Platelets count in different types of myeloproliferative 
disorders in terms of mean±SD and range. Data are illustrated 
in a relevant figure
Final diagnosis No Platelets count (×103)/µl
Mean ± SD Range
CML 35 393.0 ± 254.9 59–1173
Myelofibrosis 22 218.9 ± 170.4 15.4–716
ET 9 748.5 ± 290.6 100.8–1184
PV 9 543.3 ± 256.1 156–1043.7
p-value 0.0001*
Hematological indices, in terms of RBCs, they 
show a broad spectrum from anemia to erythrocytosis. 
The other related indices (Hg, MCV, MCH, MCHC, and 
RDW) follow a similar pattern from very low to very high 
levels.
Similarly, the platelet count varies from very 
low to very high counts.
Regarding WBCs, MPNs show signs of 
hypercellularity, in the form of a high number of WBCs, 
notably in CML. Other MPNs also have shown high 
WBCs count but much less than CML. This is also 
evident with neutrophil counts that are very high count 
with CML but much less with other MPNs. 
In terms of eosinophils count, the CML and 
ET show elevated counts, while PV and myelofibrosis 
show counts within normal limits. 
In terms of basophils, all MPNs show elevated 
counts.
These changes in blood indices reflect the 
dominant pathology affecting the bone marrow, whether 
it is hypercellularity or fibrotic in nature.
MPNs are well known for being more common 
in males than females. Our study shows male-to-female 
ratio to be 1.2, which is compatible with a Norwegian 
study male-to-female ratio is 1.2 for all MPNs [8]. 
Another Swedish study has shown male-to-female 
ration as 1.07 [9].
CML occurs more commonly in males across all 
age groups [8]. Norwegian registry constantly reported 
a male-to-female ratio 1.2–1.7 [10]. In our study, the 
ratio is 0.94. This can be explained by the low number 
of cases included in our study.
Regarding myelofibrosis, in our study, the male-
to-female ratio is 2.14. Although it is more prevalent in 
males, the ratio is higher than that of the Swedish study, 
in which the ratio is 1.48 [9]. A study that was conducted 
in the USA has shown that the ratio is 1.83 [11]. 
Obviously, the prevalence in males is higher and this 
could be explained by the high exposure to benzene and 
toluene which are well known to be causative agents for 
myelofibrosis [12], [13], [14]. Toluene and benzene are 
natural ingredients of crude oil and gasoline [15]. Iraq 
is known to be highly polluted with these compounds 
as these compounds come from motor engines fuel 
combustion [16]. Iraq has an electricity shortage; thus, 
diesel generators are in every street emitting a lot of toxic 
fumes that would contain the carcinogenic compounds 
in addition to those emitted from cars.
Regarding ET, our study shows a male-to-
female ratio of 0.5. This is compatible with the US study 
that shows the ratio to be 0.77 [11], while the Swedish 
study shows the ratio to be 0.81 [9].
Regarding PV, our study shows male-to-female 
ratio to be 2. This is compatible with the US study that 
shows a ratio of 1.83 [11], while the Swedish study 
reported a ratio of 1.48 [9].
Gender variations in MPN are not specific to 
hematological malignancies. Many diseases, such as 
acute lymphoblastic leukemia, chronic lymphocystic 
leukemia, and multiple myeloma, have shown similar 
discordance in sexual prevalence [17].
Although the etiological cause of this discord 
is obscure, the complement of the sex chromosome/
aberrations/aneuploidy, influence of sex hormones, 
all contribute to immune competence, and gene 
expression [18], [19].
Research into these factors would be beyond 
the scope of this study, but in future studies, it would be 
worth exploring. The previous studies have shown that 
thrombotic risk typically differs among subtypes of MPN 
by sex [20].
The platelet count is much higher in CML 
and PV females, 415.9 ± 291.2 × 103 plt/µL and 
763.7 ± 243.14 × 103 plt/µL, respectively, as compared 
with CML and PV males 368.6 ± 216.13 × 103 plt/µL 
and 433.11 ± 193.84 × 103 plt/µL, respectively, with 
a statistical significance p < 0.0001 as calculated by 
ANOVA test.
This finding explains the higher risk of 
developing thrombotic complications as mentioned by 
ECLAP study; female PV patients were more likely than 
males to suffer thrombotic complications (11% vs. 8%), 
particularly within the splanchnic system [21].
Gender also appears to influence the location 
of vascular events. A recent investigation identified that 
women were more likely to experience macro thrombosis 
within the abdominal venous system (hepatic, portal, 
mesenteric, or splenic veins), whereas males were more 
likely to experience events in the deep venous system, 
including limb thrombosis and pulmonary emboli [22]. 
While gender influence on thrombosis remains unclear, 
increasing evidence suggests that in the thrombotic 
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cascade, the type and ratio of circulating sex hormones 
play a significant role [17].
Limitations of the study were the low number of 
patients and the unavailability of advanced techniques 
(mentioned in the introduction) like the genetic study to 
confirm the diagnosis.
One obstacle that we have faced is the high 
number of dry tap which affected 21/74 (28.3%) of bone 
marrow aspirates. Basically, the dry tap is relatively 
common finding with bone marrow aspirates. A study 
conducted in Pakistan reported the prevalence of 
9.5% of all bone marrow aspirates, while another study 
conducted in the USA showed a ratio of 3.9% [23]. 
Dry tap occurs when there is a fibrotic reaction that is 
primary like in myelofibrosis, or secondary reaction to 
hypercellularity which is a common finding in MPNs [24].
Conclusions
MPN male-to-female ratio in Iraq, which is 
1.2. CML, is the most common subtype. Regarding 
myelofibrosis, in our study, the male-to-female ratio 
is 2.14, which is much higher in other countries. This 
could be attributed to high exposure to benzene and 
toluene which are well known to be causative agents 
for myelofibrosis. Regarding ET or PV, the male-to-
female ratios were compatible with other countries. The 
platelet count is much higher in CML and PV females 
than males. This explains the higher risk of thrombotic 
complications in such patients.
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